Sugi Predict

Sugi Predict / Compounds / SCHEMBL1663553

SCHEMBL1663553

SCHEMBL1663553

Cc1c(C(=O)O)cnn1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.50
▸ NPC1 O15118 5/20 0.50
▸ RAB9A P51151 5/20 0.50
▸ KDM4E B2RXH2 9/20 0.48
▸ ALDH1A1 P00352 5/20 0.48
▸ MAPT P10636 3/20 0.47
▸ LMNA P02545 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ TP53 P04637 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ SPR P35270 2/20 0.44
▸ HPGD P15428 2/20 0.42
▸ POLB P06746 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GAA P10253 2/20 0.41
▸ APOBEC3A P31941 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ NOTUM Q6P988 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17995092 0.98 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL32683581 0.86 KDM4E (0.44) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL17007945 0.83 RAB9A (0.47) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL1641560 0.83 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL3050197 0.81 RAB9A (0.49) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL6397435 0.81 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL12447414 0.78 KDM4E (0.47) SMN1; SMN2KDM4EALDH1A1HSD17B10TDP1
SCHEMBL68535 0.78 PDE10A (0.41) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL7722135 0.78 KDM4E (0.41) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1
SCHEMBL966692 0.78 KDM4E (0.41) SMN1; SMN2NPC1RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 — — EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 — — US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 — — WO claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 — — US disclosed
CN-112055710-B As LPA antagonists Cyclohexylacid pyrazole azine 百时美施贵宝公司 2025-01-28 — — CN disclosed
CN-112041029-B Cyclic compounds as LPA antagonists pyrazole hexyl acid 百时美施贵宝公司 2025-01-24 — — CN disclosed
CN-111699180-B Pyrazole N-linked carbamoyl cyclohexyl acid as LPA antagonist 百时美施贵宝公司 2024-11-29 — — CN disclosed
CN-112041302-B Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists 百时美施贵宝公司 2024-11-19 — — CN disclosed
EP-1176140-A1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2002-01-30 — — EP disclosed
EP-0752992-B1 IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AVENTIS PHARMA SA (FR) 2001-05-30 — — EP disclosed
CN-1058490-C Tetrazolinone derivatives BAYER AGROCHEM KK (JP) 2000-11-15 — — CN disclosed
EP-0695748-B1 Tetrazolinone herbicides BAYER AGROCHEM KK (JP) 1999-05-06 — — EP disclosed
EP-0752992-A1 IMIDAZO(1,2-A)INDENO(1,2-E)PYRAZINE-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 1997-01-15 — — EP disclosed
US-5589439-A HERBICIDES NIHON BAYER AGROCHEM K.K. (JP) 1996-12-31 — — US disclosed
CN-1122333-A Tetrazolinone derivatives BAYER AGROCHEM KK (JP) 1996-05-15 — — CN disclosed
EP-0695748-A1 Tetrazolinone herbicides NIHON BAYER AGROCHEM K.K. (JP) 1996-02-07 — — EP disclosed
WO-1995026350-A1 IMIDAZO(1,2-A)INDENO(1,2-E)PYRAZINE-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1995-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH SMN1; SMN2 3345/4885NPC1 212/4885RAB9A 1784/4885
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 SMN1; SMN2 3850/4885NPC1 3479/4885RAB9A 3406/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 SMN1; SMN2 4664/4885NPC1 4204/4885RAB9A 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.